Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation - 01/07/16
Doi : 10.1016/j.jaci.2016.02.046
Holger Garn, PhD a, Sabine Bahn, MD, PhD b, Bernhard T. Baune, MD, PhD c, Elisabeth B. Binder, MD d, Hans Bisgaard, MD e, Talal A. Chatila, MD, PhD f, Triantafyllos Chavakis, MD g, Carsten Culmsee, PhD h, Udo Dannlowski, MD i, m, Steffen Gay, MD j, James Gern, MD k, Tari Haahtela, MD l, Tilo Kircher, MD m, Ulf Müller-Ladner, MD n, Markus F. Neurath, MD, PhD o, Klaus T. Preissner, MD p, Christoph Reinhardt, PhD q, Graham Rook, MD r, Shannon Russell, PhD s, Bernd Schmeck, MD t, Thaddeus Stappenbeck, MD, PhD u, Ulrich Steinhoff, PhD v, Jim van Os, MD w, Scott Weiss, MD, PhD x, Michael Zemlin, MD y, Harald Renz, MD a, ⁎ 
a Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, University of Marburg, Marburg, Germany
h Institute for Pharmacology and Clinical Pharmacy, University of Marburg, Marburg, Germany
v Institute of Medical Microbiology, University of Marburg, Marburg, Germany
y Children's Hospital, University of Marburg, Marburg, Germany
b Centre for Neuropsychiatric Research, Cambridge University, Cambridge, United Kingdom
c Discipline of Psychiatry, University of Adelaide, Adelaide, Australia
d Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
e Faculty of Health Sciences, COPSAC, University of Copenhagen, Copenhagen, Denmark
f Boston Children's Hospital, Harvard University, Boston, Mass
g Clinical Pathobiochemistry, Technical University Dresden, Dresden, Germany
i Department of Psychiatry, University of Munster, Munster, Germany
j Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
k Division Allergy and Immunology, Clinical Science Center, Madison, Wis
l Skin and Allergy Hospital, University Hospital Helsinki, Helsinki, Finland
m Department of Psychiatry and Psychotherapy, University of Marburg, Marburg, Germany
n Clinic of Rheumatology and Clinical Immunology, University of Giessen, Giessen, Germany
p Department of Biochemistry, Medical Faculty, University of Giessen, Giessen, Germany
o Medical Clinic of Gastroenterology, Pneumonology, Endocrinology, University of Erlangen, Erlangen, Germany
q Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany
r Centre for Clinical Microbiology, University College London, London, United Kingdom
s Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
t Institute for Lung Research, Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL), Philipps-University Marburg, and the Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Marburg, Germany
u Department of Pathology and Immunology, Washington University, St Louis, Mo
w Department of Psychiatry and Psychology, Maastricht University, Maastricht, The Netherlands
x Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
∗Corresponding author: Harald Renz, MD, Institute of Laboratory Medicine, Philipps University Marburg, Baldinger Straße, 35043 Marburg, Germany.Institute of Laboratory MedicinePhilipps University MarburgBaldinger StraßeMarburg35043Germany
Abstract |
Recent research indicates that chronic inflammatory diseases, including allergies and autoimmune and neuropsychiatric diseases, share common pathways of cellular and molecular dysregulation. It was the aim of the International von-Behring-Röntgen Symposium (October 16-18, 2014, in Marburg, Germany) to discuss recent developments in this field. These include a concept of biodiversity; the contribution of urbanization, lifestyle factors, and nutrition (eg, vitamin D); and new mechanisms of metabolic and immune dysregulation, such as extracellular and intracellular RNAs and cellular and mitochondrial stress. Epigenetic mechanisms contribute further to altered gene expression and therefore to the development of chronic inflammation. These novel findings provide the foundation for further development of preventive and therapeutic strategies.
Le texte complet de cet article est disponible en PDF.Key words : Chronic inflammation, immune dysregulation, metabolism, environment, epigenetics, stress, biodiversity
Abbreviations used : Del-1, eRNA, GR, IBD, miRNA
Plan
| Supported by the von-Behring-Röntgen-Foundation, LOEWE Excellence Centre UGMLC (Universities of Gießen & Marburg Lung Centre), the Deutsches Zentrum für Lungenforschung (DZL), and the Deutsche Forschungsgemeinschaft DFG FOR 2107 (grants. KI 588/14-1, DA 1151/5-1, AFI 11802, RE 737/23-1, RE 3450/3-1, RE 3450/5-1) and SFB1021. |
|
| Disclosure of potential conflict of interest: H. Garn has received grants from Deutsche Forschungsgemeinschaft, LOEWE Excellence Centre UGMLC, Deutsches Zentrum für Lungenforschung. S. Bahn has received a grant and travel support from the University of Cambridge, has received a consulting fee or honorarium from Myriad Genetics, and is a board member for Psynova Neurotech. B. T. Baune is a board member for Lundbeck, has consultant arrangements with Lundbeck, is employed by the University of Adelaide, and has received grants from the National Health and Medical Research Council. H. Bisgaard has received grants from the Lundbeck Foundation, the Danish Ministry of Health, and the Danish Strategic Research Foundation and has consultant arrangements with Chiesi Pharmaceuticals and Boehringer Ingelheim. T. A. Chatila has received a grant from the National Institutes of Health (NIH; 1R56AI117983-01). T. Chavakis has received grants from Deutsche Forschungsgemeinschaft and the NIH and has a US patent application pending on the role of developmental endothelial locus 1 in periodontitis. C. Culmsee has received grants and travel support from DFG (DFG-FOR 2107) and AFI (AFI #11802) and has received a grant from the European Union–Framework Programme 7. U. Dannlowski has received a grant from Deutsche Forschungsgemeinschaft (DA 1151/5-1). J. Gern has received grants from the NIH, GlaxoSmithKline, and Merck; has consultant arrangements with GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Genentech, Amgen, and Novartis; and has stock/stock options in 3V BioSciences. T. Haahtela has received payment for lectures from Merck Sharp Dohme and Orion Pharma. T. Kircher has received a grant from Deutsche Forschungsgemeinschaft (KL 588/14-1) and has received fees for participation in review activities from Servier. M. F. Neurath has received travel support from von-Behring-Röntgen-Foundation; has consultant arrangements with Merck Sharp Dohme, PPM Services S.A., Index Pharmaceuticals, Shire, Tillotts Pharma, Boehringer Ingelheim, and Pentax; has received grants from the German Research Council and German Cancer Aid; has received payment for lectures from AbbVie, Boehringer Ingelheim, Celgene Corporation, Falk Foundation, Ferring, Merck Sharp Dohme, Janssen, and Takeda; has received payment for manuscript preparation from Thieme Verlag, Bayerisches Ärzteblatt, e. Bavarian Health GmbH; has a patent for anti–IL-12 therapy in patients with Crohn disease; and has received royalties from Thieme Verlag, VG Wort. C. Reinhardt has received grants from Deutsche Forschungsgemeinschaft (DFG) individual grants (RE 3450/3-1, RE 3450/5-1), CTH Junior Group Translational Research in Thrombosis and Hemostasis (BMBF 01EO1003), and Stiftung Pathobiochemie und Molekulare Diagnostik project grant. G. Rook has received travel support from the University of Marburg and Gießen. B. Schmeck has received grants from the German Research Council (DFG), the German Ministry of Education and Research (BMBF), and GlaxoSmithKline and has received payment for lectures from Novartis. H. Renz has received grants from Deutsche Forschungsgemeinschaft (RE 737/23-1, RE 3450/3-1, RE 3450/5-1), Deutsches Zentrum für Lungenforschung, LOEWE Excellence Centre UGMLC, von-Behring-Röntgen-Foundation. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 138 - N° 1
P. 47-56 - juillet 2016 Retour au numéro
Article précédent
- Interferons and inflammasomes: Cooperation and counterregulation in disease
- Larisa I. Labzin, Mario A.R. Lauterbach, Eicke Latz
- United Nations Climate Change Conferences: COP21 a lost opportunity for asthma and allergies and preparing for COP22
- Isabella Annesi-Maesano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?